BeyondSpring Files US/China NDAs for Novel Neutropenia Prevention Drug

BeyondSpring, a New York City cancer biopharma, submitted NDAs to US and China regulators of a novel prevention treatment for chemotherapy-induced neutropenia (CIN). The company combines plinabulin with granulocyte colony-stimulating factor (G-CSF), the current standard of care. BeyondSpring says G-CSF treatment is most beneficial in Week 2 after chemotherapy, leaving patients vulnerable during Week 1, the so called “neutropenia vulnerability gap” when over 75% of CIN-related clinical complications occur. More details.... Stock Symbol: (NSDQ: BYSI) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.